
Christian Britschgi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1835703/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clinical Cancer Research, 2022, 28, 1117-1126.	7.0	52
2	Frequency, molecular characteristics, and therapeutic targeting of ROS1 oncogenic fusions in colorectal cancer Journal of Clinical Oncology, 2022, 40, 160-160.	1.6	0
3	Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clinical Lung Cancer, 2022, 23, 320-332.	2.6	5
4	Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. Cancers, 2022, 14, 75.	3.7	3
5	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma, 2021, 2021, 1-12.	1.3	4
6	Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E–Mutated Metastatic Colorectal Cancer. JCO Precision Oncology, 2021, 5, 1082-1087.	3.0	9
7	When SUV Matters: FDG PET/CT at Baseline Correlates with Survival in Soft Tissue and Ewing Sarcoma. Life, 2021, 11, 869.	2.4	7
8	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. Journal of Clinical Oncology, 2021, 39, 2872-2880.	1.6	183
9	Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue – A pilot study. Experimental and Molecular Pathology, 2021, 123, 104705.	2.1	1
10	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. JAMA Oncology, 2020, 6, 100.	7.1	68
11	The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events. Immunobiology, 2020, 225, 152009.	1.9	18
12	Severe reaction to radiotherapy provoked by hypomorphic germline mutations in <i>ATM</i> (ataxia–telangiectasia mutated gene). Molecular Genetics & Genomic Medicine, 2020, 8, e1409.	1.2	8
13	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 1299.	2.8	20
14	Genome-wide non-invasive prenatal testing in single- and multiple-pregnancies at any risk: Identification of maternal polymorphisms to reduce the number of unnecessary invasive confirmation testing. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 19-29.	1.1	7
15	Temporal activation of WNT/l²-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. Oncogene, 2020, 39, 4132-4154.	5.9	23
16	Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunology, Immunotherapy, 2020, 69, 1605-1613.	4.2	6
17	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial Journal of Clinical Oncology, 2020, 38, 9016-9016.	1.6	27
18	Establishment of a tissue microarray (TMA) platform as an efficient tool for soft tissue sarcoma (STS) research available for collaboration Journal of Global Oncology, 2019, 5, 38-38.	0.5	0

#	Article	IF	CITATIONS
19	Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiation Oncology, 2018, 13, 102.	2.7	44
20	Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. Clinical Cancer Research, 2018, 24, 6345-6354.	7.0	43
21	What's new in chemotherapy for non-small cell lung cancer?. Memo - Magazine of European Medical Oncology, 2017, 10, 123-126.	0.5	ο